###### Strengths and limitations of this study

-   Our study was conducted in large city-based paediatric hospitals and our findings are, therefore, likely to be representative of the whole population.

-   Our systematic approach for enrolment allowed the easy identification of acute gastroenteritis (AGE) cases.

-   Our study enrolled only a proportion of all reported AGE cases and only severe cases were included.

Introduction {#s1}
============

Wild-type rotavirus (RV) causes approximately 111 million gastroenteritis (GE) episodes, 25 million clinic visits, 2 million hospitalisations and over 453 000 deaths each year among children younger than 5 years of age.[@R1] [@R2] It has been reported that RV mortality is highest among the low-income countries of Asia, Africa and Latin America.[@R3] A systematic review and meta-analysis of published studies in 2009 found that the overall mortality rate associated with RV infection in children under 5 years of age in sub-Saharan Africa was 243.3 deaths/100 000 children (95% CI 187.6 to 301.7).[@R4] Globally, RV infection rates are also highest among younger children, with approximately 95% children experiencing at least one episode of RVGE by the time they reach 5 years of age.[@R5]

RVGE is characterised by fever, diarrhoea and vomiting, leading to severe dehydration and increased hospitalisation. Over 90% of children with RVGE suffer from dehydration-associated mortality due to diarrhoea and associated vomiting.[@R6] It has been suggested that RV infections are more common during the cooler months of the year and that RVGE disease burden is similar in high-income and low-income nations.[@R1] However, due to malnutrition and lack of access to appropriate treatment facilities, it is the children from the low-income countries who die more frequently.[@R1]

As improvements in hygiene and sanitation have not been accompanied by reductions in the incidence of RV-associated diseases,[@R9] vaccination against RV is, therefore, considered as a public health priority for low-income nations.[@R10] The introduction of RV vaccination could have significant benefits for children aged less than 3 years, and might help to reduce diarrhoea-associated childhood morbidity and mortality in low-income countries and RV-related hospitalisation in high-income countries.[@R11] [@R12]

The most common globally circulating RV serotypes associated with RVGE are G1, G2, G3 and G4.[@R13] In addition, G9 has emerged over the past decade as a globally important serotype.[@R14] Together, these serotypes are responsible for 95% of worldwide paediatric RVGE cases.[@R15]

The epidemiology of RV infection has been followed in several small studies conducted in Abidjan in the Republic of Ivory Coast,[@R16] but recent data for this region are limited. Nevertheless, data on RVGE disease, the number of hospitalisations and the number of emergency room (ER) visits following acute GE (AGE) are critical to formulate effective policies to control RV-related AGE and are important to fully determine the need for RV vaccines and the possible impact of their introduction.

This study was designed to estimate the proportion of RVGE among children younger than 5 years of age who were diagnosed with AGE and admitted to hospitals and ERs in the Republic of Ivory Coast. The seasonal distribution of RVGE and the prevalent RV types were also studied.

Methods {#s2}
=======

Study design {#s2a}
------------

This cross-sectional, hospital-based surveillance study was conducted across five reference paediatric hospitals in Abidjan, the Republic of Ivory Coast between December 2007 and February 2009. The study was conducted in accordance with Good Clinical Practice, Declaration of Helsinki (V.1996) and applicable local regulations. Written informed consent was obtained from parents/guardians before children were enrolled.

Children presenting AGE were identified by checking hospital and ER logbooks. Male or female children aged less than 5 years, who were hospitalised or visited ER for AGE (≥3 looser than normal stools per day with or without ≥2 episodes of vomiting within 24 h), were included in the study. Children were excluded if they acquired AGE by possible nosocomial infection (within 12 h after hospital admission).

Unique study numbers were assigned sequentially to all enrolled children in order to maintain their confidentiality. Parents/guardians were interviewed and medical records were reviewed by the site staff to complete the study questionnaire and/or case report form. Information including demography (date of birth, gender, height and weight, nutritional status and area of residence), admission date and diagnosis at admission, date of discharge and administration of oral and/or intravenous rehydration/antibiotics were recorded and encoded in the study database. Details such as body temperature, duration of diarrhoea or vomiting, treatment and behavioural symptoms were also recorded. The severity of RVGE was defined according to the Vesikari Scale (mild: score \<7; moderate: 7--10 and severe: ≥11).[@R22]

Stool samples collected within 4--10 days of the onset of GE from all enrolled children as part of the study procedures were labelled, stored at a temperature of −20°C to −70°C and then transported to the Pasteur Institute, Abidjan, within 72 h of collection for testing. RV testing was performed using the IDEIA rotavirus kit (DAKO Ltd, Cambridgeshire, UK) provided by the regional laboratory (Ivory Coast National Laboratory for Rotavirus, affiliated to the WHO regional reference laboratory located in Accra, Ghana (West Africa), at the Noguchi Memorial Institute for Medical Research). A random subset of RV-positive stool samples were subsequently tested using reverse transcriptase-PCR of the VP7 and VP4 genes followed by reverse hybridisation on a strip at the DDL Diagnostic Laboratory (Rijswijk, The Netherlands) to identify G and P genotypes and to differentiate the presence of wild-type G1 RV from the vaccine strain virus.[@R23] A visible pattern is observed on the strip after hybridisation which is specific to each genotype. As a complementary tool, sequence analysis was performed to identify the genotypes for samples that yielded an unclear pattern that could not be recognised. The resulting sequence was analysed by BLAST search against the GenBank database to determine the RV genotype.[@R23]

Analyses {#s2b}
--------

All children meeting the predefined eligibility criteria were included in the final analyses.

The occurrence of severe dehydrating RVGE (based on the Vesikari Scale[@R22]) administered treatment (including intravenous rehydration), duration of hospitalisation and outcome were all reported, together with the seasonal distribution of RVGE and the occurrence of RV types.

All statistical analyses were performed using Statistical Analysis System (SAS) V.9.2 and the graphs were generated using Microsoft Excel. Categorical data such as gender, seasonal distribution and disease severity were presented as proportions with one decimal. Burden of GE/RVGE among hospitalisations/ER visits was expressed as proportions with their 95% exact CI. Exploratory analyses of estimation of the crude OR were performed using univariate logistic regression considering RV status outcome variable. Clinical characteristics and outcome at discharge were considered as the confounding factors for this analysis. Univariate logistic regression was used to estimate the association between outcome at discharge as the dependent variable and RV status/nutritional status as the independent factor. Nutritional status was derived using the weight-for-age Z-scores based on the WHO child growth standards. Associations between these derived nutritional status and the RV positivity were analysed using the χ^2^ test with 95% exact CI. Association between the clinical characteristics before/during hospitalisation and RV status were analysed using χ^2^ and fisher\'s exact test with 95% exact CI.

Results {#s3}
=======

Demographic characteristics {#s3a}
---------------------------

A total of 1330 children (917 hospitalised and 413 visiting ER) presenting AGE were identified from hospital logs. Of these, 357 children were enrolled into the study. Informed consent was not collected for 973 children, due to parent refusal, non-collection of samples and failure of the surveillance to capture the cases. The mean age (SD) of the enrolled children was 13.6 months (±11.14 months; [table 1](#BMJOPEN2013003269TB1){ref-type="table"}).

###### 

Demographic characteristics of enrolled children (N=357)

  Characteristics   Parameters   Total (N\*=357)   Emergency room (N=161)   Hospitalised (N=196)                  
  ----------------- ------------ ----------------- ------------------------ ---------------------- ------- ------ ------
  Age (months)      N            357               --                       161                    --      196    --
  Mean              13.6         --                13.7                     --                     13.5    --     
  SD                11.14        --                11.39                    --                     10.96   --     
  Gender            Female       152               42.6                     69                     42.9    83     42.3
  Male              205          57.4              92                       57.1                   113     57.7   

\*Number of children.

†Number of children in a given category.

‡n/N×100.

A total of 332 children were included in the final analysis; 25 were excluded due to not meeting the inclusion/exclusion criteria (protocol violation) in two cases and failure to either collect or analyse the stool samples for RV in the remaining 23 children.

Among those included in the final analysis, 56.3% (187/332) children had been hospitalised and the remaining 43.7% (145/332) had visited an ER.

Proportion of GE and RVGE hospitalisations {#s3b}
------------------------------------------

The proportion of all AGE-related hospitalisations and ER visits that were diagnosed with RVGE was 30.1% (n=56; 95% CI 23.6% to 37.3%) and 26.9% (n=39; 95% CI 19.9% to 34.9%), respectively.

Most of the children hospitalised and visiting the ER due to AGE corresponded to children under 2 years of age (84.8% and 84.5%, respectively). The number of RV-positive and RV-negative children stratified by age is shown in [figure 1](#BMJOPEN2013003269F1){ref-type="fig"}. Ninety-five children (28.6%) were RV positive, of whom over 80% were aged less than 24 months. The highest number of RVGE cases was seen in children aged 6--11 months (40% (38/95); [figure 1](#BMJOPEN2013003269F1){ref-type="fig"}).

![Distribution of GE cases by RV status by age groups (N=332). GE, gastroenteritis; RV, rotavirus.](bmjopen2013003269f01){#BMJOPEN2013003269F1}

The seasonal distribution of RV-attributable GE hospitalisation is shown in [figure 2](#BMJOPEN2013003269F2){ref-type="fig"}. The number of GE cases was highest in July and August 2008 and the percentage of RV-positive cases was highest in January 2008.

![Seasonality of acute GE and RVGE hospitalisations (N=331). GE, gastroenteritis; RV, rotavirus.](bmjopen2013003269f02){#BMJOPEN2013003269F2}

Clinical characteristics of GE and RVGE hospitalisations {#s3c}
--------------------------------------------------------

Among RV-positive and RV-negative children, severe GE (score ≥11 on the Vesikari Scale) was recorded in 64.2% (61/95) and 55.5% (131/236) of children before hospitalisation, respectively ([table 2](#BMJOPEN2013003269TB2){ref-type="table"}).

###### 

Clinical characteristics of children by RV status (N=331)

  Characteristics                    RV positive (N\*=95) n† (%‡)   RV negative (N=236) n (%)   p Value
  ---------------------------------- ------------------------------ --------------------------- ------------
  Severity§ before hospitalisation                                                              
   Mild (\<7)                        6 (6.3)                        27 (11.4)                   0.2300¶
   Moderate (7--10)                  28 (29.5)                      78 (33.1)                   
   Severe (≥11)                      61 (64.2)                      131 (55.5)                  
  Symptoms before hospitalisation                                                               
   Diarrhoea                         95 (100.0)                     235 (99.6)                  1.0000\*\*
   Vomiting                          81 (85.3)                      170 (72.0)                  0.0037\*\*
   Fever                             44 (46.3)                      116 (49.2)                  0.8557¶
  Classification of nutrition                                                                   
   Overweight                        5 (5.3)                        8 (3.4)                     0.1981¶
   Adequate (normal)                 66 (69.5)                      152 (64.4)                  
   Moderately malnourished           15 (15.8)                      32 (13.6)                   
   Severely malnourished             9 (9.5)                        44 (18.6)                   
  Outcome at discharge                                                                          
   Recovered                         27 (28.4)                      40 (16.9)                   0.0145\*\*
   Ongoing GE                        68 (71.6)                      184 (78.0)                  
   Transferred                       0 (0.0)                        4 (1.7)                     
   Died                              0 (0.0)                        8 (3.4)                     

One child was excluded from analysis as RV status was not determined.

Nutritional status was derived using the weight-for-age Z-scores (WAZ).

\*Number of children.

†Number of children in a given category.

‡n/N×100.

§Severity using the 20-point Vesikari Scale.

¶χ^2^ p Value.

\*\*Fisher\'s exact test p Value.

GE, gastroenteritis; RV, rotavirus.

The percentage of children recording GE-associated symptoms (diarrhoea, vomiting and fever) was similar across RV-positive and RV-negative groups before hospitalisation. However, a significant (p=0.0037) association between vomiting and RV-positive status was observed before hospital admission ([table 2](#BMJOPEN2013003269TB2){ref-type="table"}).

Nutritional status based on weight indicated that adequately and moderately malnourished children were distributed similarly across RV-positive and RV-negative groups. However, a higher number of severely malnourished children was observed in the RV-negative group ([table 2](#BMJOPEN2013003269TB2){ref-type="table"}).

Oral rehydration was the most commonly used treatment for GE in RV-positive and RV-negative groups (70.5% and 75.8%, respectively), followed by intravenous rehydration therapy (54.7% and 53%, respectively).

At discharge, the majority of children among RV-positive and RV-negative groups (71.6% (68/95) and 78% (184/236), respectively) had ongoing GE. Eight RV-negative children (3.4%) died, of whom all but one (87.5% (7/8)) were severely malnourished. The unadjusted OR estimate indicated that severely malnourished children had 22.2 (95% CI 2.5 to 198.8) times higher risk of dying as compared with children with adequate nutritional status (p=0.0056; [table 2](#BMJOPEN2013003269TB2){ref-type="table"}).

RV-type distribution {#s3d}
--------------------

Fifty-three of 95 RV-positive stool samples were assessed for RV type in this study. The most prevalent RV types were G1P\[8\] wild-type (34% (18/53)) and G8P\[6\] (18.9% (10/53)). Mixed RV types were detected in 30.2% (16/53). The RV vaccine strain (G1P\[8\] vaccine strain) was not detected in any sample. The other detected RV types are shown in [figure 3](#BMJOPEN2013003269F3){ref-type="fig"}.

![Distribution of RV G and P types (N=331). RV, rotavirus.](bmjopen2013003269f03){#BMJOPEN2013003269F3}

Discussion {#s4}
==========

This study into RVGE disease burden found that RV infection is the primary cause of hospitalisation due to GE in children aged less than 5 years in the Republic of Ivory Coast.

We identified RV in 30.1% and 26.9% children either hospitalised or visiting an ER for AGE, respectively. This is consistent with an earlier epidemiological study in Abidjan that demonstrated the general prevalence of RVGE in children younger than 5 years to be 27.9% between 1997 and 2000.[@R21] In addition, a review of published studies (1975--1992) of RVGE in Africa detected RV in 24--29% of children hospitalised for diarrhoea.[@R9]

In the present study, RV disease burden was predominantly observed among young children (over 90% (87/95) were aged up to 23 months), which is consistent with previous studies conducted across the African continent.[@R9] A study conducted in Nigeria showed that over 90% of RVGE-positive cases were observed in children aged less than 2 years[@R24] and two independent studies conducted in Egypt (1995--1996)[@R25] and Libya (October 2007--September 2008)[@R26] indicated that the incidence of RVGE was highest among children aged 6--11 months; all comparable to the results of the present study.

As observed in previous studies conducted in sub-Saharan Africa between 1975 and 1992,[@R9] most GE cases in this study were observed between July and August 2008.

Almost all children who died following AGE in this study were severely malnourished, indicating the importance of nutritional status in potentially determining the outcome of AGE. Previous reports substantiate these findings, where malnourishment has been associated with a considerable risk of diarrhoea-associated mortality.[@R27] [@R28]

The circulation of mixed RV types in the African countries has been previously reported.[@R29] [@R30] In this study, although wild-type G1P\[8\] was the most commonly detected (34% (18/53)) RV type, several (30.2% (16/53)) mixed RV types were detected. The proportion of mixed RV types observed in this study is comparable to that reported by the WHO\'s RV surveillance in the African region.[@R31] In this report, nearly 42% of the circulating RV types during 2006--2009 comprised mixed RV types.[@R31]

There is no available antiviral therapy for RV infection,[@R32] and RVGE management predominantly includes fluid and electrolyte replacement and improvements in sanitation and water supply.[@R33] Antibiotic treatment is not justified during RVGE and its use is limited to cases with documented bacterial coinfection. However, it has been suggested that improvements in hygiene and provision of safe water may not be as effective in the prevention of RVGE as they are to GE due to other causes.[@R33]

Previous studies have established that RV vaccination confers protection against severe RVGE and has helped relieve the global burden of this disease.[@R34] These effects have been observed in similar settings in Asia, Africa and Latin America.[@R29] [@R38] [@R39] The efficacy of RV vaccines against severe RVGE has been found to be 59% in South Africa and Malawi[@R40] and 64% in Kenya, Ghana and Mali.[@R41] RV vaccination may, therefore, represent the most effective primary public health intervention against RVGE. Indeed in 2009, the WHO recommended the inclusion of RV vaccines in the routine childhood vaccine programmes of all countries.[@R42] RV vaccines are available in the private sector in the Republic of Ivory Coast, but no RV vaccine is currently included in the universal mass vaccination programme.

Data presented in this study highlight the magnitude of RV-associated disease burden and might allow policymakers to determine the need to implement prevention strategies in the Republic of Ivory Coast. Indeed, the inclusion of a RV vaccine, as a prevention strategy, might help to reduce the burden of AGE and AGE-associated hospitalisations.

The results of this study need to be interpreted in the light of several strengths and limitations. Among the strengths, the systematic approach followed in this study to identify children by checking hospital and ER logbooks enabled easy identification of AGE cases using standard case definitions. Second, the study was conducted in reference hospitals seeing over 1300 AGE cases annually, which complies with the recommendations of WHO\'s generic protocol for hospital-based RVGE in children.[@R43] By including multiple centres, these data more closely represent the local population. In addition, the quality check processes performed on the laboratory tests of RV-positive samples provide credibility to the results.

However, the study does have limitations. As a large number of children who presented with GE were not enrolled and tested for RV, the possibility of selection bias might be considered. Our reported prevalence of RVGE might have been affected by selecting only severe GE cases with more severe disease characteristics, including longer hospital stays. Nonetheless, this study provides a realistic picture of the role of RV among more severe cases of RVGE, which incur substantial direct and indirect medical costs and impact public health in this setting. It should be noted that most of the participants who were not enrolled were either not captured during surveillance or did not consent to participate in the study. Second, only 53 of 95 RV-positive stool samples were available for strain identification which limited the possibility of describing the circulating strains. Nevertheless, by using a reference laboratory with validated techniques and experience for PCR confirmation, it was possible to provide accurate estimates for the identified strains. Finally, firm conclusions regarding the seasonality of RV and the variation in circulating RV strains could not been drawn as the surveillance activities were conducted for just 1 year following recommendations from WHO.[@R43] Nevertheless, routine surveillance is warranted as RV circulation might vary from one calendar year to another.

Conclusion {#s5}
==========

RVGE in children aged less than 5 years continues to be a major public health challenge in the Republic of Ivory Coast. In our study, the disease, which peaked in July and August, mainly affected infants aged 6--11 months. Wild-type G1P\[8\] and G8P\[6\] were the most frequently reported RV types. The inclusion of a RV vaccine into local preventative programmes might, therefore, help to reduce the disease burden of RVGE.
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